Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-18 15:36 • The Motley Fool Positive Axe Cap view: Selective

Vanguard S&P 500 Growth ETF (VOOG) is recommended over Vanguard Mega Cap Growth ETF (MGK) for long-term investors. While MGK offers a slightly lower expense ratio of 0.05% versus VOOG's 0.07%, VOOG's broader diversification across 148 holdings versus MGK's 56 holdings has delivered superior returns across most time periods, with VOOG returning 22.80% over one year compared to MGK's 18.80%.

Axe note: Vanguard’s S&P 500 Growth ETF (VOOG) edges out the Mega Cap Growth ETF (MGK) thanks to broader diversification and better recent returns.

2026-07-18 15:18 • The Motley Fool Positive Axe Cap view: Selective

The Vanguard S&P 500 ETF offers a simple, low-cost way to build wealth through consistent long-term investing in 500 large U.S. companies. With a 0.03% expense ratio and historical 15% average annual returns, investing $500 monthly could yield $1.36 million over 30 years. However, investors should be aware of market volatility, tech sector concentration, and the need for patience and a diversified portfolio strategy.

Axe note: Investing regularly in the Vanguard S&P 500 ETF can create serious wealth over time, but watch out for sector concentration and volatility.

2026-07-18 13:30 • The Motley Fool Positive Axe Cap view: Selective

Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.

Axe note: Wall Street loves Viking Therapeutics’ weight-loss drug, but long trial timelines and side effect worries suggest caution.